Catalyst Pharmaceuticals, Inc. $CPRX Position Trimmed by Knott David M Jr

Knott David M Jr decreased its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 36.5% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 120,000 shares of the biopharmaceutical company’s stock after selling 69,000 shares during the quarter. Catalyst Pharmaceuticals accounts for about 1.8% of Knott David M Jr’s investment portfolio, making the stock its 18th largest position. Knott David M Jr’s holdings in Catalyst Pharmaceuticals were worth $2,971,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Advisory Services Network LLC acquired a new stake in shares of Catalyst Pharmaceuticals during the 3rd quarter valued at $39,000. Quarry LP acquired a new position in shares of Catalyst Pharmaceuticals in the 3rd quarter worth $40,000. Clearstead Advisors LLC raised its position in shares of Catalyst Pharmaceuticals by 192.9% during the fourth quarter. Clearstead Advisors LLC now owns 1,772 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 1,167 shares during the period. Smartleaf Asset Management LLC raised its position in shares of Catalyst Pharmaceuticals by 55.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 630 shares during the period. Finally, Larson Financial Group LLC raised its position in shares of Catalyst Pharmaceuticals by 552.7% during the fourth quarter. Larson Financial Group LLC now owns 1,847 shares of the biopharmaceutical company’s stock worth $43,000 after purchasing an additional 1,564 shares during the period. Institutional investors own 79.22% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on CPRX. Robert W. Baird lowered Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 7th. Stephens set a $32.00 price objective on Catalyst Pharmaceuticals in a report on Thursday, May 7th. Cantor Fitzgerald raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Friday, March 27th. Weiss Ratings raised shares of Catalyst Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, June 3rd. Finally, Citigroup cut shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $35.00 to $31.50 in a report on Friday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $32.00.

Catalyst Pharmaceuticals Price Performance

Shares of NASDAQ:CPRX opened at $31.49 on Friday. The company’s fifty day moving average is $31.38 and its two-hundred day moving average is $27.27. The company has a market cap of $3.86 billion, a P/E ratio of 18.10, a price-to-earnings-growth ratio of 0.96 and a beta of 0.74. Catalyst Pharmaceuticals, Inc. has a 12-month low of $19.05 and a 12-month high of $32.56.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).